Lisa M Ellerby

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6726480/publications.pdf

Version: 2024-02-01

47 papers	4,350 citations	201674 27 h-index	223800 46 g-index
53 all docs	53 docs citations	53 times ranked	4089 citing authors

#	Article	IF	Citations
1	PNA microprobe for label-free detection of expanded trinucleotide repeats. RSC Advances, 2022, 12, 7757-7761.	3.6	1
2	Pluripotent stem cell-derived models of neurological diseases reveal early transcriptional heterogeneity. Genome Biology, 2021, 22, 73.	8.8	6
3	Modulating FKBP5/FKBP51 and autophagy lowers HTT (huntingtin) levels. Autophagy, 2021, 17, 4119-4140.	9.1	27
4	Neuronal intranuclear inclusion disease: Polyglycine protein is the culprit. Neuron, 2021, 109, 1757-1760.	8.1	6
5	Unbiased identification of novel transcription factors in striatal compartmentation and striosome maturation. ELife, 2021, 10, .	6.0	9
6	Characterization and application of fluidic properties of trinucleotide repeat sequences by wax-on-plastic microfluidics. Journal of Materials Chemistry B, 2020, 8, 743-751.	5.8	9
7	FOXO3 targets are reprogrammed as Huntington's disease neural cells and striatal neurons face senescence with p16^{INK4a} increase. Aging Cell, 2020, 19, e13226.	6.7	17
8	Insulin-like growth factor 2 (IGF2) protects against Huntingtonâ€™s disease through the extracellular disposal of protein aggregates. Acta Neuropathologica, 2020, 140, 737-764.	7.7	43
9	Modeling Polyglutamine Expansion Diseases with Induced Pluripotent Stem Cells. Neurotherapeutics, 2019, 16, 979-998.	4.4	21
10	Repeat Expansion Disorders: Mechanisms and Therapeutics. Neurotherapeutics, 2019, 16, 924-927.	4.4	20
11	Nuclear Receptor Nr4a1 Regulates Striatal Striosome Development and Dopamine D₁Receptor Signaling. ENeuro, 2019, 6, ENEURO.0305-19.2019.	1.9	17
12	Mutant huntingtin impairs PNKP and ATXN3, disrupting DNA repair and transcription. ELife, 2019, 8, .	6.0	83
13	Altered Expression of Matrix Metalloproteinases and Their Endogenous Inhibitors in a Human Isogenic Stem Cell Model of Huntington's Disease. Frontiers in Neuroscience, 2017, 11, 736.	2.8	22
14	Using Genome Engineering to Understand Huntingtonâ€™s Disease. Research and Perspectives in Neurosciences, 2017, , 87-101.	0.4	5
15	iPSC-based drug screening for Huntington×³s disease. Brain Research, 2016, 1638, 42-56.	2.2	26
16	Genomic Analysis Reveals Disruption of Striatal Neuronal Development and Therapeutic Targets in Human Huntingtonâ€™s Disease Neural Stem Cells. Stem Cell Reports, 2015, 5, 1023-1038.	4.8	117
17	Proteolytic cleavage of ataxin-7 promotes SCA7 retinal degeneration and neurological dysfunction. Human Molecular Genetics, 2015, 24, 3908-3917.	2.9	22
18	Integration-independent Transgenic Huntington Disease Fragment Mouse Models Reveal Distinct Phenotypes and Life Span in Vivo. Journal of Biological Chemistry, 2015, 290, 19287-19306.	3.4	20

#	Article	IF	Citations
19	Polyglutamine Disease Modeling: Epitope Based Screen for Homologous Recombination using CRISPR/Cas9 System. PLOS Currents, 2014, 6, .	1.4	52
20	Histone deacetylase-3 interacts with ataxin-7 and is altered in a spinocerebellar ataxia type 7 mouse model. Molecular Neurodegeneration, 2013, 8, 42.	10.8	24
21	A Genome-Scale RNAâ€“Interference Screen Identifies RRAS Signaling as a Pathologic Feature of Huntington's Disease. PLoS Genetics, 2012, 8, e1003042.	3.5	41
22	Inhibition of Lipid Signaling Enzyme Diacylglycerol Kinase Ïµ Attenuates Mutant Huntingtin Toxicity. Journal of Biological Chemistry, 2012, 287, 21204-21213.	3.4	26
23	Caspase-6 Activity in a BACHD Mouse Modulates Steady-State Levels of Mutant Huntingtin Protein But Is Not Necessary for Production of a 586 Amino Acid Proteolytic Fragment. Journal of Neuroscience, 2012, 32, 7454-7465.	3.6	46
24	Genetic Correction of Huntington's Disease Phenotypes in Induced Pluripotent Stem Cells. Cell Stem Cell, 2012, 11, 253-263.	11.1	336
25	Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease. Journal of Huntington's Disease, 2012, 1, 195-210.	1.9	25
26	Mass Spectrometric Identification of Novel Lysine Acetylation Sites in Huntingtin. Molecular and Cellular Proteomics, 2011, 10, M111.009829.	3.8	34
27	Identification and Evaluation of Small Molecule Pan-Caspase Inhibitors in Huntington's Disease Models. Chemistry and Biology, 2010, 17, 1189-1200.	6.0	50
28	Proteolysis of Mutant Huntingtin Produces an Exon 1 Fragment That Accumulates as an Aggregated Protein in Neuronal Nuclei in Huntington Disease. Journal of Biological Chemistry, 2010, 285, 8808-8823.	3.4	259
29	Autophagy: PolyQ toxic fragment turnover. Autophagy, 2010, 6, 312-314.	9.1	14
30	Matrix Metalloproteinases Are Modifiers of Huntingtin Proteolysis and Toxicity in Huntington's Disease. Neuron, 2010, 67, 199-212.	8.1	152
31	Characterization of Human Huntington's Disease Cell Model from Induced Pluripotent Stem Cells. PLOS Currents, 2010, 2, RRN1193.	1.4	216
32	Polyglutamine-Expanded Androgen Receptor Truncation Fragments Activate a Bax-Dependent Apoptotic Cascade Mediated by DP5/Hrk. Journal of Neuroscience, 2009, 29, 1987-1997.	3.6	56
33	Posttranslational Modification of Ataxin-7 at Lysine 257 Prevents Autophagy-Mediated Turnover of an N-Terminal Caspase-7 Cleavage Fragment. Journal of Neuroscience, 2009, 29, 15134-15144.	3.6	47
34	Proteolytic Cleavage of Ataxin-7 by Caspase-7 Modulates Cellular Toxicity and Transcriptional Dysregulation. Journal of Biological Chemistry, 2007, 282, 30150-30160.	3.4	69
35	Huntingtin Interacting Proteins Are Genetic Modifiers of Neurodegeneration. PLoS Genetics, 2007, 3, e82.	3.5	368
36	Cut to the chase. Nature, 2006, 442, 641-642.	27.8	12

#	Article	IF	Citations
37	Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin. Neurobiology of Disease, 2006, 21, 381-391.	4.4	59
38	Huntingtin Phosphorylation Sites Mapped by Mass Spectrometry. Journal of Biological Chemistry, 2006, 281, 23686-23697.	3.4	131
39	Ataxin-7 Can Export from the Nucleus via a Conserved Exportin-dependent Signal. Journal of Biological Chemistry, 2006, 281, 2730-2739.	3.4	38
40	Inhibition of Calpain Cleavage of Huntingtin Reduces Toxicity. Journal of Biological Chemistry, 2004, 279, 20211-20220.	3.4	242
41	Nuclear Localization of a Non-caspase Truncation Product of Atrophin-1, with an Expanded Polyglutamine Repeat, Increases Cellular Toxicity. Journal of Biological Chemistry, 2003, 278, 13047-13055.	3.4	78
42	Kennedy's Disease. Journal of Biological Chemistry, 2003, 278, 34918-34924.	3.4	67
43	Calpain Activation in Huntington's Disease. Journal of Neuroscience, 2002, 22, 4842-4849.	3.6	282
44	Caspase Cleavage of Mutant Huntingtin Precedes Neurodegeneration in Huntington's Disease. Journal of Neuroscience, 2002, 22, 7862-7872.	3.6	344
45	Cleavage of Atrophin-1 at Caspase Site Aspartic Acid 109 Modulates Cytotoxicity. Journal of Biological Chemistry, 1999, 274, 8730-8736.	3.4	99
46	Kennedy's Disease. Journal of Neurochemistry, 1999, 72, 185-195.	3.9	211
47	Caspase Cleavage of Gene Products Associated with Triplet Expansion Disorders Generates Truncated Fragments Containing the Polyglutamine Tract. Journal of Biological Chemistry, 1998, 273, 9158-9167.	3.4	499